Objetivo: O presente estudo teve como objetivo descrever as alterações oculares em pacientes portadores de doença falciforme, na Bahia, um estado do Nordeste, que tem a maior prevalência da doença no Brasil. Métodos: Nós conduzimos um estudo de corte transversal em um grupo de 146 (292 olhos) pacientes com Doença Falciforme (90 HBSS e 56 HBSC). Para exame oftalmológico foi realizada oftalmoscopia binocular indireta complementada pela retinografia fluorescente para detecção de lesões retinianas decorrentes da Doença Falciforme. Resultados: As lesões mais frequentemente encontradas foram o aumento da tortuosidade vascular e “black sumburst” Retinopatia proliferativa foi encontrada em 22 (12,2%) olhos de pacientes HBSS e 25 (22,3%) olhos de pacientes HBSC (OR=2.06; CI95%: 1.5-4.06, p=0.022); essa frequência foi maior entre os pacientes HBSS com idade entre 20 - 39 anos, enquanto que nos pacientes HBSC foi maior nos acima de 40 anos (35.7% e 42.8%), decaindo abruptamente após essa idade. Conclusão: Retinopatia proliferativa foi descrita por volta dos dez anos de idade em ambos os grupos. A prevalência da retinopatia falciforme proliferativa pode resultar em cegueira e o conhecimento das alterações oculares mais prevalentes e idade de risco destas em pacientes com Doença Falciforme será importante para estabelecer um protocolo de acompanhamento oftalmológico, para prevenir um dano visual clinicamente grave, aumentando a qualidade de vida destes pacientes.
Descritores: Anemia falciforme; Doença de hemoglobina SC; Traumatismos oculares; Doenças retinianasObjective: The present study aims to describe ocular alterations in sickle cell disease patients in Bahia, a Northeast state, with the highest prevalence of the disease in Brazil. Methods: We carried out a cross-sectional study in a group of 146 (292 eyes) sickle cell disease patients (90 HBSS and 56 HBSC). Ophthalmologic examination including indirect binocular ophthalmoscopy was performed. Examination was completed by fluorescein angiography to detect retinal lesions. Results: The most frequent ocular lesions identified were “vascular tortuosity” and “black sunburst”. Proliferative retinopathy was found in 22 (12.2%) eyes of HBSS patients and 25 (22.3%) eyes of HBSC patients (OR=2.06; CI95%: 1.5-4.06, p=0.022); Its frequency was higher among HBSS patients aged 20-39 years, while in HBSC patients, it peaked after 40 years (35.7% and 42.8%) and dropped sharply afterwards. Conclusion: Proliferative retinopathy was described as early as 10 years of age in both patients groups. Proliferative sickle retinopathy can result in blindness and the knowledge of the most prevalent ocular alterations and age risk will be important to establish a protocol of ophthalmologic follow-up, in order to prevent a severe visual loss and increase patient's life quality.
Keywords: Anemia, sickle cell; Hemoglobin SC disease; Eye injuries; Retinal diseases
The sickle cell hemoglobin (HbS) is characterized
by a single nucleotide change (GAG?GTG) in
the sixth codon of the ß-globin gene, which leads
to a valine instead of glutamine in the sixth position of
the ß-globin chain.(1)
Because of its decreased solubility under
deoxygenated conditions, hemoglobin S polymerizes in
red blood cells, forming a highly ordered fiber aggregates
that distort the cells’ shape into an elongated forms. The
polymer makes reversible and irreversible changes in
sickle cell erythrocytes and is responsible for the sickle
cell phenotype, including the homozygous state of HBSS
and heterozygous combinations such as HBSC and HBS-ß
thalassemia that have a less severe manifestations than
those found in sickle cell anaemia patients. The sickle
cell trait (HBAS) is an exception and is not considered a
sickle cell disease since the carriers do not have any
clinical manifestations.(1)
The overall frequency of HbS is high worldwide,
and in Brazil its distribution is heterogeneous. In
Northeastern Brazil, mainly in Bahia, the population is a
tri-racial mixture of Europeans (mostly Portuguese),
Africans and indigenous.(2) The frequency of HbS in the
state of Bahia is the highest in Brazil, varying from 4.5 to
14.7% in several population groups studied.(3)
The sickle cell disease is characterized by a
variety of clinical abnormalities frequently linked to
hemolytic anaemia and vaso-occlusive processes, which
are responsible for causing pain and other clinical
features such as retinopathy.(1,4)
Ocular lesions results from stasis and occlusion of
the small eye vessels by sickled erythrocytes. Transient
dark red spots, representing plugs of sickled erythrocytes
within superficial capillaries can be seen on the surface
of the optic disc and conjunctiva. Vaso-occlusive disease
of the retina can be responsible for nonproliferative and
proliferative ocular changes. The nonproliferative lesions
consist of ocular lesions such as a “salmon patches”, vessel
tortuosity, “black sunbursts”, iridescent spots and angioid
streaks that characterize hemorrhagic, infarctive, and
resolving lesions of sickle retinopathy.(1) Proliferative
ocular lesions can result in partial or total loss of vision
and are classified into different clinical stages. Stage I is
characterized by arteriolar obstruction; stage II, by
arteriovenous anastomoses; stage III, by neovascularization;
stage IV, by vitreous hemorrhage and stage
V, by retinal detachment.(5)
Despite the high prevalence of sickle cell disease
in Bahia and the high frequency of ocular changes in
sickle cell disease patients, there have been no studies of
these alterations with sickle cell retinopathy in Bahia, a
state with African ethnic characteristics.(2) We therefore
consider important to characterize the ocular lesions
found among sickle cell patients from northeast Brazil.
This study was approved by the Oswaldo Cruz
(Research Foundation’s Human Research Ethics
Committee), and informed consent was obtained in
accordance with ethical principles and the Helsinki
Declaration of 1975, and by the Brazilian resolution 196/
96, of the Ministry of Health, Law 6,638/79 and
Normative Resolution 04/97. Ophthalmologic
examinations were carried out, and peripheral blood
samples were collected only after signed informed
consent was obtained.
The cross-sectional study involved a group of 146
(292 eyes) sickle cell patients (90 HBSS and 56 HBSC)
from the State of Bahia in northeast Brazil and was
carried out between july, 2002, and april, 2006.
The patients were selected among those attending
the hematology ambulatory at the Bahia Foundation of
Hematology and Hemotherapy (HEMOBA), a reference
center attending to sickle cell disease patients who are
seen in routinely visits. Patients were then sent to the
Brazilian Institute of Ophthalmology and Blindness
Prevention (IBOPC) for an ocular examination, including
fundus biomicroscopy, indirect binocular ophthalmoscopy
and fluorescein angiography when the retinopathy could
not be adequately characterized solely by means of a
fundoscopic examination. We observed the following in
the fundoscopic examination: vascular tortuosity,
alterations of papila, “salmon patches”, angioid streaks
and iridescent spots. The pathologic classification of
fundoscopic alterations as proliferative was based on
Goldberg’s five-stage groups; stage I - peripheral arteriolar
occlusions, stage II - peripheral arteriovenous anastomoses,
stage III - preretinal neovascularization, stage IV - vitreous
hemorrhage and stage V - retinal detachment.
Patients presenting with proliferative retinopathy
were separated by age and classified as severe when
displaying stages III to V when retinal neovascularization
was seen. The hemoglobin pattern was confirmed at the
Pathology and Molecular Biology Laboratory of Fiocruz
and UFBA using High Performance Liquid Chromatography
(HPLC - VARIANT I / BIO-RAD, CA, USA).
EpiInfo software for Windows, version 3.3.2 was used
to store and analyze data. The Chi-squared Pearson's test
or the Fisher’s exact test was used when necessary to compare
both groups of hemoglobinopathy carriers. A p-value
of less than 0.05 was considered statistically significant.
The number of sickle cell disease patients enrolled
in the study was 146 (292 eyes): 90 (61.6%) with sickle
cell anemia or HBSS and 56 (38.4%) with HBSC disease.
The majority of these patients (58.9%) were from Salvador,
and the others came from other cities in the state.
Overall, the patients had an average age of 26.7 (+ 11.6)
years. The HBSS patients group had an average age of
26.7 (+10.1) years and the HBSC group had an average
age of 26.9 (+13.9) years. Eighty-four (57.5%) were
women, and 62 (42.5%) were men. Among the HBSS
patient group, there were 39 (43.3%) men and 51 (56.7%)
women, while among the HBSC group, there were 23
(41.1%) men and 33 (58.9%) women. Statistically nonsignificant
differences were found when comparing the
age (p=0.625) of the HBSS and HBSC patients. There
were no significant differences in gender (p=0.923) when
comparing both patient groups studied.
Two HBSC disease patients had an intraocular
pressure = 20mmHg; however, no overall change in
intraocular pressure was observed among the different
patient groups. Visual acuity was 20/20 or 20/25 for the
best eye in 133 patients, corresponding to 91.1% of the
total number of cases.
Age-related ocular lesions, including
nonproliferative and proliferative lesions, were very
frequent among both groups of patients (HBSS and
HBSC). Table 1 shows the ocular lesion distribution across
six age groups. The HBSS group had more ocular changes
in the age range of 20-39. In the HBSC group of patients
these changes became more frequent in the age range of
40 to more than 50 years.
Vascular tortuosity and “black sunbursts” were the
most frequent fundoscopic ocular lesions found in both
sickle cell disease groups (HBSS and HBSC ). Table 2
shows that the vascular tortuosity percentage was similar
in both sickle cell disease patients’ groups. The “black
sunburst” was more frequent in the HBSC disease group.
The frequency of “salmon patches” and angioid streaks,
however, was low in both groups, and the disc-shaped
signal and iridescent spots were only found in the HBSS
group.
In both the HBSS and HBSC disease groups, there
were patients with proliferative ocular lesions; however,
the HBSC group had more proliferative ocular lesions
than the HBSS group.
The HBSS group had more severe ocular disease
in the age range of 30-39 than the HBSC group. Table 3
shows the distribution of proliferative ocular lesions across
six age groups related to stages I to V and III to V. The
HBSS group had the highest frequency of proliferative
changes, mainly in the age range of 20-39. The HBSC
patient group had more ocular changes in the age range
of 40-49. Table 4 shows that the HBSC group had more
cases of proliferative ocular lesions per eye than the HBSS
group. Figure 1 shows fluorescein angiography of
peripheral arteriolar occlusions, peripheral arteriovenous
anastomoses, preretinal neovascularization and extensive
capillary non-perfusion from a 31-year-old woman with
sickle cell anemia (HBSS ).
Several ocular changes were observed in the
studied patient groups; however, no change in visual
acuity was found, as previously reported.(5-10)
With regard to the fundoscopic lesions, vascular
tortuosity and “black sunbursts” were the most frequent
changes identified, corroborating previous Brazilian
studies.(7-10) The overall frequency of vascular tortuosity
was similar in both patient groups (HBSS and HBSC ), as
previously described.(10,11) The “black sunburst” lesion
was seen in both groups, although its frequency in HBSC
patients was much lower than that described in other
studies.(10,12,13) The low frequency of other ocular lesions
such as the disc sign and iridescent spots could be
attributed to their transient status and to the fact that
they do not produce clinically visual impairment that
requires serial follow-up testing.(14)
Proliferative retinopathies were significantly
more frequent in the HBSC group than in HBSS group,
as described previously.(1,7,15-17) When the HBSC patients
were stratified according to age, however, we observed
two peaks of ocular changes, one between 10 and 19 years
of age and another between 40 and 49 years of age that
subsequently dropped sharply. This finding is in contrast
to previous studies.(15,18,19) Indeed, Fox et al.(18) studied
Jamaican patients and observed that ocular proliferative
lesions increased with age in both genotypes.
Interestingly, the HBSS patients had more severe
proliferative changes (stages III to V) between the ages
of 10 to 19 years and 30 to 39 years when compared to
the HBSC group, characterizing an elevated frequency
when compared with others studies.(20,21) On the basis
of our results, additional studies are warranted to determine
if these findings are related to an increase of vasoocclusive
crisis among these specific ages or with the
presence of others biomarkers for assessing relative risk
in these group of SCA patients.
This is the first study of ocular lesions among
HBSS and HBSC patients from Bahia. The lower
percentage of severe proliferative retinopathy found
among HBSS patients when compared to HBSC patients
could be attributed to auto infarction or a spontaneous
regression of proliferative retinopathies, a phenomenon
described in sickle cell disease.(21) A milder disease
phenotype was previously described among these
patients,(22,23) protecting against the early vessel
occlusion described in HBSS1 and contributing to
proliferative lesion development among the older
patients. In addition, the age-related variation in
proliferative lesions observed in HBSC patients could
be related to more severe anemia, resulting in a
decrease in blood viscosity. The results presented here
show that sickle cell disease patients from Bahia could
have specific risk factors for retinal vessel changes other
that those described before.(24,26)
In conclusion, the ocular lesions described here
could help to define the clinical and ophthalmologic
protocols of HBSS and HBSC patient’s follow-up in
specific ages. The presence of proliferative ocular
alterations are a well documented cause of blindness
and the knowledge of the most prevalent ocular
alterations and age risk of these in HBSS and HBSC
patients will be important to establish ophthalmologic
follow-up protocols, preventing a severe visual loss.
Further studies, including the association between ocular
lesions and hematological, environmental and genetic
factors - in a larger number of HBSS and HBSC patients
in Brazil should contribute to improving patient quality
of life, bringing new knowledge of ophthalmologic
alterations among these patients.
Acknowledgements
We thank the medical staff of the institutions
where the study was developed and parents and patients
whose gave their informed consent to participate in the
study. This study was supported by CNPq, DECIT contract
grant numbers: 305427/2007-7 (MSG); and 409800/2006-
6 (MSG); FAPESB / UNESCO, contract grant number:
013/03 (MSG).
| 1. |
Ohene-Frempong K, Steinberg MH. Clinical aspects of sickle cell anemia in adults and children. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin: genetics, phatophysiology and clinical management. New York: Cambridge University Press; 2001. p.611-670. |
| 2. |
Azevêdo ES, Fortuna CM, Silva KM, Sousa MG, Machado MA, Lima AM, et al. Spread and diversity of human populations in Bahia, Brazil. Hum Biol. 1982; 54(2): 329-41. |
| 3. |
Azevêdo ES, Alves AF, Da Silva MC, Souza MG, Muniz Dias Lima AM, Azevedo WC. Distribution of abnormal hemoglobins and glucose- 6-phosphate dehydrogenase variants in 1200 school children of Bahia, Brazil. Am J Phys Anthropol. 1980; 53(4):509-12. |
| 4. |
Vilela RQ, Bandeira DM, Silva MA. Alterações oculares nas doenças falciformes/ Ocular complications in sickle cell disease. Rev Bras Hematol Hemoter. 2007; (29):285-7. |
| 5. |
Goldberg MF. Classification and pathogenesis of proliferative sickle cell retinopathy. Am J Ophthalmol. 1971;71(3)):649-65. |
| 6. |
Condon PI, Serjeant GR. Ocular findings in hemoglobin SC disease in Jamaica. Am J Ophthalmol. 1972;74(5):921-31. |
| 7. |
Bonanomi MT, Cunha SL, Araújo JT. Funduscopic alterations in SS and SC hemoglobinopathies. Study of a Brazilian population. Ophthalmologica. 1988;197(1):26-33. |
| 8. |
Popma SE. Ocular manifestation of sickle hemoglobinopathies. Clin Eye Vis Care. 1996;8(2): 111-7. |
| 9. |
Akinsola FB, Kehinde MO. Ocular findings in sickle cell disease patients in Lagos. Niger Postgrad Med J. 2004;11(3):203-6. |
| 10. |
Garcia CA, Fernandes MZ, Uchôa UB, Cavalcante BM, Uchôa RA. Achados fundoscópicos em crianças portadoras de anemia falciforme no Estado do Rio Grande do Norte. Arq Bras Oftalmol. 2002;65(6):615-8. |
| 11. |
Fox PD, Minninger K, Forshaw ML, Vessey SJ, Morris JS, Serjeant GR. Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease. Eye (Lond). 1993; 7(Pt 5): 703-6. |
| 12. |
Moriarty BJ, Acheson RW, Condon PI, Serjeant GR. Patterns of visual loss in untreated sickle cell retinopathy. Eye (Lond). 1988; 2(Pt3): 330-5. |
| 13. |
Welch RB, Goldberg MF. Sickle-cell hemoglobin and its relation to fundus abnormality. Arch Ophthalmol. 1966; 75(3):353-62. |
| 14. |
Condon PI, Serjeant GR. Ocular findings in elderly cases of homozygous sickle-cell disease in Jamaica. Br J Ophthalmol. 1976; 60(5):361-4. |
| 15. |
Goldbaum MH, Jampol LM, Goldberg MF. The disc sign in sickling hemoglobinopathies. Arch Ophthalmol. 1978; 96(9): 1597-600. |
| 16. |
Oliveira FV, Aihara T, Cançado RD. Alteraçöes fundoscópicas nas hemoglobinopatias SS e SC . Arq Bras Oftalmol. 1996;59(3):234-8. |
| 17. |
Moraes Junior HV, Araújo PC, Brasil OF, Oliveira MV, Cerqueira V, Turchetti R. Achados oculares em doença. Rev Bras Oftalmol. 2004; 63(5/6):299-302. |
| 18. |
Fox PD, Dunn DT, Morris JS, Serjeant GR. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. 1990; 74(3):172-6. |
| 19. |
Gagliano DA, Goldberg MF. The evolution of salmon-path hemorrhages in sickle cell retinopathy. Arch Ophthalmol. 1989; 107(12):1814-5. |
| 20. |
Clarkson JG. The ocular manifestations of sickle-cell disease: a prevalence and natural history study. Trans Am Ophthalmol Soc. 1992; 90:481-504. |
| 21. |
Bonanomi MT. Neovascularizaçäo da retina em hemoglobinopatia SC e hemorragia. Arq Bras Oftalmol. 1997; 60(1):24-33. |
| 22. |
Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Neovascularizaçäo da retina em hemoglobinopatia. Ophthalmology. 2005; 112(11):1869-75. |
| 23. |
Lyra IM, Goncalves MS, Braga JA, Gesteira Mde F, Carvalho MH, Saad ST, et al. Clinical, hematological, and molecular characterization of sickle cell anemia pediatric patients from two different cities in Brazil. Cad Saude Publica. 2005;21(4):1287-90. |
| 24. |
Goncalves MS, Bomfim GC, Maciel E, Cerqueira I, Lyra I, Zanette A et al. BetaS-haplotypes in sickle cell anemia patients from Salvador, Bahia, Northeastern Brazil. Braz J Med Biol Res. 2003; 36(10):1283-8. |
| 25. |
Lima CS, Rocha EM, Silva NM, Sonatti MF, Costa FF, Saad ST. Risk factors for conjunctival and retinal vessel alterations in sickle cell disease. Acta Ophthalmol Scand. 2006; 84(2): 234-41. |
| 26. |
Diallo JW, Sanfo O, Blot I, Meda N, Sawadogo P, Quedraogo A, Simporé J. [Epidemiology and prognostic factors for sickle cell retinopathy in Ouagadougou (Burkina Faso). J Fr Ophtalmol. 2009; 32(7):496-500. |
Copyright 2008. Todos os direitos reservados a SBO - Sociedade Brasileira de Oftalmologia